PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD

Key research on felzartamab highlights the long-lasting effects of CD38-targeted therapy and its potential for improved outcomes in patients with IgA nephropathy (IgAN), emphasizing the promise of immune-targeted treatment. In an interview with HCPLive, Jürgen Floege, MD, senior professor at RWTH Aachen University’s Medical School, discusses the future of the therapy for IgAN. "There was a proteinuria reduction. That's no big surprise. Sounds funny, but it's like what everybody else is seeing today. We have 10 drugs under development and they all have similar proteinuria reductions. But the particular thing with felzartamab is that the proteinuria reduction persists when you stop treatment, even when you stop treatment for one and a half years. And my feeling is patients will like that. Patients will like to go through a course of treatment and then don't think about it." Read more: https://www.hcplive.com/view/prevail-... #nephrology #IGaN #chronickidneydisease